This article appears in the following Annals of Oncology issue: ESMO Clinical Recommendations [View the issue table of contents]
ESMO clinical recommendations |
Testicular non-seminoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
1 Department of Oncology/Haematology/Haemostaseology, University Hospital Halle, Halle, Germany
2 Department of Academic Radiotherapy, Institute of Cancer Research, Royal Marsden Hospital, Sutton Hospital, UK
3 Department of Urology, AMC University Hospital, Amsterdam, The Netherlands
4 Department of Medicine, Institute Gustave Roussy, Villejuif, France
5 Department of Oncology, Kuopio University Hospital, Kuopio and Vaasa Central Hospital, Vaasa, Finland
* Correspondence to: ESMO Guidelines Working Group, ESMO Head Office, Via L. Taddei 4, CH-6962 Viganello-Lugano, Switzerland. E-mail: clinicalrecommendations{at}esmo.org
 |
incidence |
|---|
 Top incidence diagnosisstaging and risk assessmenttreatment of primary tumourtreatment of TINpost-operative treatmenttreatment of non-seminoma stage...treatment of non-seminoma stage...treatment of advanced non...management after primary...monitoring during and after...salvage chemotherapylate relapselate toxicityfollow-upnoteacknowledgementsreferences |
|---|
The incidence of testicular cancer in Europe is rising with doubling every 20 years. The current incidence is 63/100 000/year, with the highest rate in Northern European countries (68/100 000/year). The death rate is very low (3.8 cases/100 000/year). Of testicular tumours, 40% are seminomas and 60% non-seminomas. Invasive testicular cancer develops from carcinoma in situ (CIS)/testicular intraepithelial neoplasia (TIN), often found in the residual nonmalignant testicular tissue. In a random biopsy, 2%–5% of testicular cancer patients have CIS in the contralateral testis. This is in accordance with a 2%–3% rate of synchronous contralateral or metachronous testicular cancer.
|
diagnosis |
|---|
|
Topincidencediagnosisstaging and risk assessmenttreatment of primary tumourtreatment of TINpost-operative treatmenttreatment of non-seminoma stage...treatment of non-seminoma stage...treatment of advanced non...management after primary...monitoring during and after...salvage chemotherapylate relapselate toxicityfollow-upnoteacknowledgementsreferences |
|---|
The diagnosis is based on histology of testicular mass removed by inguinal orchiectomy or by testis-conserving surgery [IV, B].
Biopsy or, instead, high 
-fetoprotein (AFP) and/or human chorionic gonadotropin (HCG) without biopsy in patients presenting with extragonadal tumour syndrome [IV, B].
In advanced and rapidly progressive disease requiring urgent chemotherapy, diagnosis may be based on typical clinical picture and marker elevation alone.
Germ cell tumour may present extragonadally in the retroperitoneum or mediastinum in a minority of cases.
|
staging and risk assessment |
|---|
|
Topincidencediagnosisstaging and risk assessmenttreatment of primary tumourtreatment of TINpost-operative treatmenttreatment of non-seminoma stage...treatment of non-seminoma stage...treatment of advanced non...management after primary...monitoring during and after...salvage chemotherapylate relapselate toxicityfollow-upnoteacknowledgementsreferences |
|---|
Full blood count, creatinine, electrolytes and liver enzymes should be obtained. Tumour markers [AFP, β-HCG and lactate dehydrogenase (LDH)] are needed for risk assessment according to UICC/IGCCCG stage and prognostic index. Markers are determined before orchiectomy and repeated a minimum of 7 days after orchiectomy (for differentiation of stage and IGCCCG prognostic group). HCG must be followed until normalization.
Testicular sonography (7.5 MHz transducer) should be conducted, also noting the size of the contralateral testis. CT scan of chest, abdomen and pelvis [III, B]. MRI of the central nervous system is needed only in advanced stages or with symptoms. Bone scan should be conducted in case of indicators for involvement (e.g. symptoms).
PET scanning does not contribute and routine use is not recommended [I, B].
If fertility is an issue, the following should be conducted: determination of total testosterone, lutenizing hormone (LH) and follicle-stimulating hormone (FSH) before operation, semen analysis and sperm banking (before chemotherapy).
In case of a borderline lymph node size in imaging (normal <1 cm) CT scan should be repeated 6 weeks later before defining definitive treatment strategy.
If imaging is normal tumour marker decline should be monitored until normalization in order to discriminate stage I and disseminated disease.
Early consultation of an oncologist is mandatory.
Definition of stage and risk classification must be done according to the UICC/American Joint Committee on Cancer (AJCC) and IGCCCG classification (Table 1).
|
For histology, the World Health Organisation (WHO) classification must be used and the report must specify the tumour localization, size, multiplicity, extension of tumour (e.g. in rete testis or other tissue), pT category (UICC), histopathological type (WHO) and presence of syncytiotrophoblasts. In pluriform tumours each individual component should be described, with percentage presence or absence of vascular invasion (venous or lymphatic) and presence of TIN.
|
treatment of primary tumour |
|---|
|
Topincidencediagnosisstaging and risk assessmenttreatment of primary tumourtreatment of TINpost-operative treatmenttreatment of non-seminoma stage...treatment of non-seminoma stage...treatment of advanced non...management after primary...monitoring during and after...salvage chemotherapylate relapselate toxicityfollow-upnoteacknowledgementsreferences |
|---|
Orchiectomy is standard of care and partial orchiectomy may be performed in specific indications [II, B].
Surgery of the primary should be performed before any further treatment, unless there is life-threatening metastatic disease and clear clinical diagnosis of germ cell tumour by marker elevation which requires immediate chemotherapy.
Tumour marker analysis should be performed before surgery and, if elevated, 7 days after surgery to determine the half-life kinetics. Tumour markers should be monitored until normalization. Markers should be taken after surgery, even if normal.
radical orchiectomy
Radical orchiectomy is performed through an inguinal incision [II, A]. Any scrotal violation for biopsy or open surgery should be avoided strongly. Tumour-bearing testis is resected with the spermatic cord at the level of the internal inguinal ring.
A frozen section is recommended in doubtful cases (of small tumours) before definitive surgery [II, B], to allow organ-sparing surgery.
organ-preserving surgery/partial orchiectomy
Radical orchiectomy may be avoided and replaced by organ-preserving surgery; however, only in highly experienced centres and, in particular, in case of synchronous bilateral testicular tumours, metachronous contralateral (second) testicular tumour, tumour in a solitary testis and sufficient endocrine function, and contralateral atrophic testis.
After local resection the spared testicular tissue always contains TIN, which can be destroyed by adjuvant radiotherapy. This can and should be delayed in patients who wish to father children, but for a period as short as possible.
contralateral biopsy for diagnosis of TIN
Some 3%–5% of testicular cancer patients have TIN in the contralateral testis with the highest risk (
34%) with testicular atrophy (volume <12 ml) and age <40 years, and in patients with extragonadal germ cell tumour prior chemotherapy (33%), but only in 10% post-chemotherapy. If untreated, invasive testicular tumour develops in 70% of the TIN-positive testis within 7 years.
The sensitivity and specificity of one random biopsy for the detection of TIN is very high. Therefore, patients should be informed about the potential risk of TIN and a contralateral biopsy should be offered. However, patients themselves should be given the opportunity to decide whether a biopsy should be done or only monitoring performed—assuming the same high level of survival (nearly 100%) whatever strategy is chosen.
If the patient has had chemotherapy a biopsy should not be taken <2 years from treatment.
|
treatment of TIN |
|---|
|
Topincidencediagnosisstaging and risk assessmenttreatment of primary tumourtreatment of TINpost-operative treatmenttreatment of non-seminoma stage...treatment of non-seminoma stage...treatment of advanced non...management after primary...monitoring during and after...salvage chemotherapylate relapselate toxicityfollow-upnoteacknowledgementsreferences |
|---|
If TIN has been diagnosed the options include immediate definitive treatment, surveillance with delayed active treatment or no treatment. The strategy should be chosen by the patient depending on the individual needs, in particular if fertility is an issue. However, fertility potential per se is often very low in this group of patients. If fertility has to be maintained, definitive treatment should be delayed and substituted by active surveillance until conception followed by either active treatment or further surveillance. If fertility is not relevant, irradiation with 16–20 Gy (2 Gy fraction, 5x/week) [III] should be performed (the strongest evidence is for 20 Gy).
In patients with TIN and no gonadal tumour (incidental diagnosis, e.g. by biopsy for infertility or extragonadal germ cell tumours) orchiectomy is preferred over irradiation, because of potential damage to the contralateral, non-affected testis by scattered radiation.
For TIN in patients receiving chemotherapy, chemotherapy eradicates TIN in two-thirds of patients. Therefore, treatment for TIN is only indicated if re-biopsy after chemotherapy is considered; however, not earlier than 2 years after chemotherapy. Instead of definitive treatment for TIN, it is strongly suggested to follow up the patient by monitoring alone, including the possibility of a (re)biopsy.
|
post-operative treatment |
|---|
|
Topincidencediagnosisstaging and risk assessmenttreatment of primary tumourtreatment of TINpost-operative treatmenttreatment of non-seminoma stage...treatment of non-seminoma stage...treatment of advanced non...management after primary...monitoring during and after...salvage chemotherapylate relapselate toxicityfollow-upnoteacknowledgementsreferences |
|---|
Patients should be treated by oncologists with experience in the management of testicular cancer. In early stage non-seminoma there are several treatment options with different treatment burden and toxicities. The patient must be well informed about the different treatment modalities, their acute and late toxicities, and the overall outcome.
If treatment is performed correctly, the cure rate of patients with non-seminoma in stage I is 
99%, in stage IIA/B 98% and in advanced disease with good prognosis 90%, intermediate prognosis 80% and poor prognosis 60%.
|
treatment of non-seminoma stage I |
|---|
|
Topincidencediagnosisstaging and risk assessmenttreatment of primary tumourtreatment of TINpost-operative treatmenttreatment of non-seminoma stage...treatment of non-seminoma stage...treatment of advanced non...management after primary...monitoring during and after...salvage chemotherapylate relapselate toxicityfollow-upnoteacknowledgementsreferences |
|---|
Stage I patients are divided into low risk (20% relapse rate) or high risk (40%–50% relapse rate) according to absence or presence of vascular (lymphatic or venous) invasion. The prognosis is excellent (98%–100%), whichever management option is used. The choice should be made on the basis of acute and late toxicities, overall treatment burden and personal preferences, including fertility issues associated with family planning. Sperm banking should be offered if active treatment is chosen. However, two or even four cycles of PEB are associated with a high level of residual fertility after recovery from chemotherapy-associated damage.
The number of cycles of adjuvant chemotherapy is a current research topic. The option of one cycle of PEB is prospectively compared with the current standard of two cycles of PEB, with preliminary data indicating that one cycle of PEB might be sufficient [IIA].
treatment of low-risk non-seminoma stage I
The standard option for low risk without vascular invasion is surveillance (Table 2). If surveillance is not applicable (e.g. no possibility to follow up by markers and imaging), adjuvant chemotherapy with two cycles of PEB is recommended.
|
treatment of high-risk non-seminoma stage I
There are two treatment options: surveillance or adjuvant chemotherapy (two cycles of PEB).
risks and benefits. Both options should be discussed, including detailed information about risks and benefits. The survival is the same (99%) whichever option is used.
surveillance: Relapse rate 40%–50%; therefore chemotherapy (three cycles of PEB) eventually required for only 50% of the patients.
adjuvant chemotherapy: Relapse rate 3%–4%, but chemotherapy (two cycles of PEB) used for 100% of the patients.
role of RPLND in stage I low-/high-risk patients
For very restricted cases, only if surveillance or adjuvant chemotherapy is declined by the patient due to very specific or personal reasons, a nerve-sparing RPLND may be considered. This treatment has the highest treatment burden with the lowest efficacy and should be performed by specialized surgeons only, in order to minimize complications including loss of ejaculation. The risk of relapse is reduced but not eliminated (e.g. lung metastases).
|
treatment of non-seminoma stage IIA/B |
|---|
|
Topincidencediagnosisstaging and risk assessmenttreatment of primary tumourtreatment of TINpost-operative treatmenttreatment of non-seminoma stage...treatment of non-seminoma stage...treatment of advanced non...management after primary...monitoring during and after...salvage chemotherapylate relapselate toxicityfollow-upnoteacknowledgementsreferences |
|---|
These stages belong to the IGCCCG good prognosis category.
Stage IIA, marker-negative
There are two equivalent strategies.
strategy 1. Only follow-up every 6 weeks until either regression/normalization or progression with treatment accordingly (Table 3).
|
strategy 2. Active treatment with either biopsy or nerve-sparing RPLND.
Both options have the same overall result. Further management depends on the results of the follow-up or RPLND (Table 4).
|
stage IIA, marker-positive, or stage IIB, marker-positive or -negative
The standard treatment is chemotherapy with PEB for three cycles (Table 3). PE for four cycles may be used if there are arguments against the use of bleomycin.
In case of complete response no further treatment is necessary. In case of residual tumour (>1 cm lymph node diameter) resection of this residual lesion should be performed, followed by routine follow-up (independent of the result of the resection).
|
treatment of advanced non-seminoma stage IS/IIC/III |
|---|
|
Topincidencediagnosisstaging and risk assessmenttreatment of primary tumourtreatment of TINpost-operative treatmenttreatment of non-seminoma stage...treatment of non-seminoma stage...treatment of advanced non...management after primary...monitoring during and after...salvage chemotherapylate relapselate toxicityfollow-upnoteacknowledgementsreferences |
|---|
The treatment options for advanced non-seminoma with good, intermediate and poor prognosis are given in Table 4. This table also gives the individual steps for further management depending on the result of the primary chemotherapy, including secondary surgery after chemotherapy and salvage treatment.
Patients with good prognosis receive three cycles of PEB. PEB can be given as classical 5- or -3 day protocol [I, B]. If there are arguments against the use of bleomycin, e.g. factors predisposing for bleomycin-induced acute or cumulative pneumonitis/fibrosis, PEB can be substituted by PEI (
VIP) for three cycles.
In intermediate and poor prognosis patients PEB for four cycles is standard, given as 5-day schedule. Since four cycles are given, the 3-day schedule should not be applied [I, B]. As in good prognosis, PEB can be substituted in case of factors against the use of bleomycin by PEI (VIP) for four cycles.
Chemotherapy cycles must be repeated every 3 weeks, independent of leukocyte count but with platelet recovery above 100 000 count (at day 22); only in this case and in case of infection at day 22 the next cycle should be delayed until recovery.
Supportive management with prophylactic use of G-CSF or antibiotics and modern antiemetic therapy (5HT3 antagonist + steroid ± NK-1 antagonist) are recommended.
|
management after primary chemotherapy |
|---|
|
Topincidencediagnosisstaging and risk assessmenttreatment of primary tumourtreatment of TINpost-operative treatmenttreatment of non-seminoma stage...treatment of non-seminoma stage...treatment of advanced non...management after primary...monitoring during and after...salvage chemotherapylate relapselate toxicityfollow-upnoteacknowledgementsreferences |
|---|
If restaging 4 weeks after the last treatment cycle reveals elevated markers and/or residual tumour, the next steps depend on the individual situation of the patient.
In principal, any residual tumour must be resected if there is no marker increase within the first weeks after termination of chemotherapy.
In case of a marker plateau, the resection should be delayed since there is a good chance that this represents a ‘pseudo-marker plateau’ resulting from necrotic tumour tissue which still is resolving and liberating tumour markers into blood. These patients should be followed up in short intervals until markers have been normalized or the final decision with respect to the resection can be done.
In case of multiple metastases in several organs or brain or liver, resection is probably not appropriate and the indications and extend of resection should be discussed with experts and treated at specialized centres.
Further management depends on the result of the primary treatment and secondary surgery. In case of complete response or R0-resection with scar tissue only or differentiated teratoma or viable tumour <10% of the resected specimen, follow-up is recommended, whereas in case of >10% viable tumour, consolidation chemotherapy with, for example, two cycles of VIP should be considered [III].
In case of incomplete resection of viable tumour and/or residual tumour, salvage chemotherapy should be applied, as well as in case of relapse from CR or progression after marker normalization in case of unresectable residual lesions.
|
monitoring during and after treatment |
|---|
|
Topincidencediagnosisstaging and risk assessmenttreatment of primary tumourtreatment of TINpost-operative treatmenttreatment of non-seminoma stage...treatment of non-seminoma stage...treatment of advanced non...management after primary...monitoring during and after...salvage chemotherapylate relapselate toxicityfollow-upnoteacknowledgementsreferences |
|---|
Tumour markers must be determined before every cycle. Four weeks after the last cycle, determination of tumour markers as well as imaging (chest X-ray, CT scan or MRI of the initial sites) should be conducted.
A PET scan is regarded as experimental (should not be performed outside of clinical trials).
|
salvage chemotherapy |
|---|
|
Topincidencediagnosisstaging and risk assessmenttreatment of primary tumourtreatment of TINpost-operative treatmenttreatment of non-seminoma stage...treatment of non-seminoma stage...treatment of advanced non...management after primary...monitoring during and after...salvage chemotherapylate relapselate toxicityfollow-upnoteacknowledgementsreferences |
|---|
Relapse after a longer (>3 months) period following initial favourable response does not always represents a platinum-resistant situation. Cisplatin is part of salvage treatment protocols, preferably together with further agents which have not been used in the first-line treatment. After second-line and, in some cases, also after third-line treatment, chemosensitivity may still be present.
Standard first-line salvage chemotherapy is standard dose VIP, TIP or VeIP. There is no proven benefit of high-dose chemotherapy either in first- or second-line salvage treatment in any patient subgroup.
In refractory patients, e.g. those who never reach a marker-negative complete response after first-line treatment or have no favourable response after salvage treatment, no standard treatment can be recommended. Gemcitabine/paclitaxel may be considered as an option. High-dose chemotherapy in this setting is experimental and should only be performed in clinical trials. Surgery should be part of the strategy, particularly in those patients with localized or late relapse, and with poor response to chemotherapy. Patients should be included in clinical trials and referred to expert centres whenever possible.
|
late relapse |
|---|
|
Topincidencediagnosisstaging and risk assessmenttreatment of primary tumourtreatment of TINpost-operative treatmenttreatment of non-seminoma stage...treatment of non-seminoma stage...treatment of advanced non...management after primary...monitoring during and after...salvage chemotherapylate relapselate toxicityfollow-upnoteacknowledgementsreferences |
|---|
If technically feasible, radical surgical resection of all lesions should be performed, irrespective of the level of tumour markers, particularly in poor responders to chemotherapy. If the lesions are not completely resectable, at least a biopsy should be obtained for histological assessment. Salvage chemotherapy should be initiated.
Late relapses (when chemotherapy has been used as part of management) respond less well to new chemotherapy (often yolk sac tumour, AFP-positive, slow-growing teratoma). If the patient responds to salvage chemotherapy, secondary surgery should be conducted whenever possible.
|
late toxicity |
|---|
|
Topincidencediagnosisstaging and risk assessmenttreatment of primary tumourtreatment of TINpost-operative treatmenttreatment of non-seminoma stage...treatment of non-seminoma stage...treatment of advanced non...management after primary...monitoring during and after...salvage chemotherapylate relapselate toxicityfollow-upnoteacknowledgementsreferences |
|---|
There is a 3% risk of developing contralateral testis tumour during the first 15 years (if TIN has not been diagnosed or diagnosed and treated prophylactically by radiation). There is a risk of secondary cancer, including leukaemia, gastrointestinal carcinoma, genitourinary cancer, lung cancer and sarcoma, particularly in previously irradiated fields.
Chemotherapy-related late toxicity includes cardiovascular disease and metabolic syndrome (hypercholesterolemia, hypertension and diabetes), hypogonadism, persisting neurotoxicity, Raynaud's syndrome and ototoxicity.
|
follow-up |
|---|
|
Topincidencediagnosisstaging and risk assessmenttreatment of primary tumourtreatment of TINpost-operative treatmenttreatment of non-seminoma stage...treatment of non-seminoma stage...treatment of advanced non...management after primary...monitoring during and after...salvage chemotherapylate relapselate toxicityfollow-upnoteacknowledgementsreferences |
|---|
Relapses are most commonly detected by marker elevation.
A reduced number of CT scans during follow-up is as effective as a higher frequency [I, B] (evidence level only for stage I).
All other recommendations are not prospectively proven, but may serve as a basis for clinical practice (Table 5). Follow-up beyond 5 years is probably relevant to detect late toxicities or secondary cancer for early intervention.
|
|
note |
|---|
|
Topincidencediagnosisstaging and risk assessmenttreatment of primary tumourtreatment of TINpost-operative treatmenttreatment of non-seminoma stage...treatment of non-seminoma stage...treatment of advanced non...management after primary...monitoring during and after...salvage chemotherapylate relapselate toxicityfollow-upnoteacknowledgementsreferences |
|---|
Levels of evidence [I–V] and grades of recommendation [A–D] as used by the American Society of Clinical Oncology are given in square brackets. Statements without grading were considered justified standard clinical practice by the experts and the consensus conference panel.
|
acknowledgements |
|---|
|
Topincidencediagnosisstaging and risk assessmenttreatment of primary tumourtreatment of TINpost-operative treatmenttreatment of non-seminoma stage...treatment of non-seminoma stage...treatment of advanced non...management after primary...monitoring during and after...salvage chemotherapylate relapselate toxicityfollow-upnoteacknowledgementsreferences |
|---|
The manuscript is based on the results of an expert panel discussion, organized and financed by an educational grant of the European Society of Medical Oncology (ESMO) in association with the ESMO Symposium on Testicular Cancer, EIS in May 2008 and was performed as a formal expert consensus conference. Members of the consensus conference panel are H-J Schmoll (Chair), Germany; MP Laguna (Co-chair), The Netherlands; K Fizazi (Co-chair), France; A Horwich (Co-chair), UK; P Albers, Germany; W Albrecht, Germany; F Algaba, Spain; I Bodrogi, Hungary; C Bokemeyer, Germany; G Cohn-Cedermark, Sweden; S Culine, France; M Cullen, UK; G Daugaard, Denmark; M De Santis, Austria; R De Wit, The Netherlands; G Derigs, Germany; K Dieckmann, Germany; JP Droz, France; L Einhorn, USA; A Fléchon, France; S Fossa, Norway; RS Foster, USA; J Garcia del Muro Solans, Spain; T Gauler, Germany; L Géczi, Hungary; JR Germa Lluch, Spain; S Gillessen, Switzerland; M Gosporadowicz, Canada; JT Hartmann, Germany; M Hartmann, Germany; R Huddart, UK; M Jewett, Canada; J Joffe, UK; K Jordan, Germany; V Kataja, Finland; O Klepp, Norway; S Kliesch, Germany; C Kollmannsberger, Canada; S Krege, Germany; L Looijenga, The Netherlands; GM Mead, UK; A Necchi, Italy; C Nichols, USA; N Nicolai, Italy; T Oliver, UK; D Ondrus; Slovak Republic; W Osterhuis, The Netherlands; L Paz-Ares, Spain; T Powles, UK; T Pottek, Germany; E Rajpert-De Meyts, Denmark; G Rosti; Italy; G Rustin, UK; R Salvioni, Italy; H Schmidberger, Germany; F Sedlmayer, Austria; A Sella, Israel; C Sippel, Germany; NE Skakkebaek, Denmark; R Souchon, Germany; A Sohaib, UK; S Tjulandin, Russia; AW van den Belt-Dusebout, The Netherlands; H von der Maase, Denmark; P Warde, Canada; L Wood, Canada.
|
footnotes |
|---|
Approved by the ESMO Guidelines Working Group: April 2002, last update March 2009. This publication supercedes the previously published version—Ann Oncol 2008; 19 (Suppl 2): ii52–ii54.
Conflict of interest: Prof. Schmoll, Dr Jordan, Dr Laguna, Prof. Horwich, Prof. Fizazi and Dr Kataja have reported no conflicts of interest. Prof. Huddart has not reported any conflicts of interest.
|
references |
|---|
|
Topincidencediagnosisstaging and risk assessmenttreatment of primary tumourtreatment of TINpost-operative treatmenttreatment of non-seminoma stage...treatment of non-seminoma stage...treatment of advanced non...management after primary...monitoring during and after...salvage chemotherapylate relapselate toxicityfollow-upnoteacknowledgementsreferences |
|---|
1. Stephenson AJ, Bosl GJ, Motzer RJ, et al. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer. J Clin Oncol (2007) 25:5597–5602.
2. Saxman SB, Finch D, Gonin R, Einhorn LH. Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience. J Clin Oncol (1998) 16:702–706.[Abstract]
3. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol (1997) 15:594–603.
4. Schmoll HJ, Souchon R, Krege S, et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol (2004) 15:1377–1399.
5. Krege S, Beyer J, Souchon R, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol (2008) 53:478–496.[CrossRef][Web of Science][Medline]
6. Krege S, Beyer J, Souchon R, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol (2008) 53:497–513.[CrossRef][Web of Science][Medline]
7. van As NJ, Gilbert DC, Money-Kyrle J, et al. Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse. Br J Cancer (2008) 98:1894–1902.[CrossRef][Web of Science][Medline]
8. Groll RJ, Warde P, Jewett MA. A comprehensive systematic review of testicular germ cell tumor surveillance. Crit Rev Oncol Hematol (2007) 64:182–197.[CrossRef][Web of Science][Medline]
9. Read G, Stenning SP, Cullen MH, et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol (1992) 10:1762–1768.
10. Cullen MH, Stenning SP, Parkinson MC, et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol (1996) 14:1106–1113.
11. de Wit R, Roberts JT, Wilkinson PM, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol (2001) 19:1629–1640.
12. Nichols CR, Catalano PJ, Crawford ED, et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol (1998) 16:1287–1293.
13. Rustin GJ, Mead GM, Stenning SP, et al. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197—The National Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol (2007) 25:1310–1315.
14. de Wit R, Fizazi K. Controversies in the management of clinical stage I testis cancer. J Clin Oncol (2006) 24:5482–5492.
15. Huddart R, Kataja V. Mixed or non-seminomatous germ-cell tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol (2008) 19(Suppl 2):ii52–ii54.
16. Pico JL, Rosti G, Kramar A, et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol (2005) 16:1152–1159.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. T. Nguyen, A. Z. Fu, T. D. Gilligan, B. J. Wells, E. A. Klein, M. W. Kattan, and A. J. Stephenson Defining the Optimal Treatment for Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer Using Decision Analysis J. Clin. Oncol., January 1, 2010; 28(1): 119 - 125. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||